90Y-ibritumomab B cell non-Hodgkin's Infusion of 250mg/m2 Rituximab infusion reaction
Prolonged and severe tiuxetan (Zevalin) lymphoma not responding rituximab (not included …

Patients with low-grade, follicular non-Hodgkin's lymphoma usually present with advanced
disease, which is not considered curable with conventional therapies. New approaches are …

We retrospectively evaluated our single-center clinical experience with 90Y-ibritumomab
tiuxetan and 131I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We …

The median survival for patients with advanced indolent non-Hodgkin's lymphoma (NHL)
has remained at 7 to 8 years since the 1960s. Targeted treatment using …

Radioimmunotherapy is a promising new therapeutic option for the treatment of B-cell non-
Hodgkin's lymphoma. Several monoclonal antibody and radionuclide conjugates, including I …

This was a 30-patient Phase II trial of reduced-dose 90Y ibritumomab tiuxetan (Zevalin™)
RIT for patients with low-grade, follicular, or transformed B-cell NHL and mild …

90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first
radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a …

Yttrium 90 ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) was the first
radioimmunotherapeutic agent approved by the US Food and Drug Administration. It is …

Abstract Background In January 2004, EMEA approved 90 Y-radiolabelled ibritumomab
tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or …

Radioimmunotherapy is an emerging clinical treatment option for non-Hodgkin's lymphoma
(NHL) that combines the target specificity of monoclonal antibodies with the cytotoxicity of …